IDH 突变在癌症中的生物学作用和治疗潜力。
Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
机构信息
Department of Pathology, Duke University, Durham, NC, USA; The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
Department of Pathology, Duke University, Durham, NC, USA; The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC, USA.
出版信息
Cancer Cell. 2018 Aug 13;34(2):186-195. doi: 10.1016/j.ccell.2018.04.011. Epub 2018 May 24.
Abstract
Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by competitively inhibiting α-ketoglutarate-dependent dioxygenases involved in histone and DNA demethylation. Small-molecule inhibitors of mutant IDH1 and IDH2 have been developed and are progressing through pre-clinical and clinical development. In this review, we provide an overview of mutant IDH-targeted therapy and discuss a number of important recent pre-clinical studies using models of IDH-mutant solid tumors.
摘要
热点突变发生在异柠檬酸脱氢酶 1（IDH1）和异柠檬酸脱氢酶 2（IDH2）在各种髓系恶性肿瘤和实体瘤中。突变 IDH 蛋白获得新的酶活性，产生假定的致癌代谢物 D-2-羟基戊二酸，据认为通过竞争性抑制参与组蛋白和 DNA 去甲基化的α-酮戊二酸依赖性加双氧酶，阻止细胞分化。已经开发出突变 IDH1 和 IDH2 的小分子抑制剂，并正在进行临床前和临床开发。在这篇综述中，我们概述了突变 IDH 靶向治疗，并讨论了一些使用 IDH 突变型实体瘤模型的重要的最新临床前研究。
相似文献
1
Biological Role and Therapeutic Potential of IDH Mutations in Cancer.IDH 突变在癌症中的生物学作用和治疗潜力。
Cancer Cell. 2018 Aug 13;34(2):186-195. doi: 10.1016/j.ccell.2018.04.011. Epub 2018 May 24.
2
IDH mutations in cancer and progress toward development of targeted therapeutics.癌症中的异柠檬酸脱氢酶（IDH）突变与靶向治疗药物研发进展
Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013.
3
Targeting isocitrate dehydrogenase (IDH) in cancer.在癌症中靶向异柠檬酸脱氢酶（IDH）。
Discov Med. 2016 May;21(117):373-80.
4
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.异柠檬酸脱氢酶突变作为胶质瘤的治疗靶点。
Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11.
5
Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.异柠檬酸脱氢酶（IDH）抑制作为治疗髓系恶性肿瘤的方法：进展与未来方向。
Pharmacol Ther. 2017 Sep;177:123-128. doi: 10.1016/j.pharmthera.2017.03.003. Epub 2017 Mar 14.
6
Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.新型靶向癌症异柠檬酸脱氢酶突变治疗药物的研发。
Curr Top Med Chem. 2018;18(6):505-524. doi: 10.2174/1568026618666180518091144.
7
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic Mutations.AG-221，一种针对携带致癌突变的急性髓系白血病的首创疗法。
Cancer Discov. 2017 May;7(5):478-493. doi: 10.1158/2159-8290.CD-16-1034. Epub 2017 Feb 13.
8
Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.分子途径：癌症中的异柠檬酸脱氢酶突变
Clin Cancer Res. 2016 Apr 15;22(8):1837-42. doi: 10.1158/1078-0432.CCR-13-1333. Epub 2016 Jan 27.
9
The role of IDH mutations in acute myeloid leukemia.IDH 突变在急性髓系白血病中的作用。
Future Oncol. 2018 Apr;14(10):979-993. doi: 10.2217/fon-2017-0523. Epub 2018 Mar 15.
10
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.突变型异柠檬酸脱氢酶1和异柠檬酸脱氢酶2抑制剂在急性髓系白血病治疗中的作用。
Ann Hematol. 2017 Dec;96(12):1983-1991. doi: 10.1007/s00277-017-3161-0. Epub 2017 Oct 31.
引用本文的文献
1
Nuclear functional role of metabolic enzymes and related metabolites: Focus on gene expression regulation.代谢酶及相关代谢物的核功能作用：聚焦于基因表达调控。
Mol Metab. 2025 Aug 7;100:102233. doi: 10.1016/j.molmet.2025.102233.
2
Biliary tract cancers: advances in diagnostic and management.胆道癌：诊断与管理的进展
Explor Target Antitumor Ther. 2025 Jun 23;6:1002328. doi: 10.37349/etat.2025.1002328. eCollection 2025.
3
Comprehensive GC-MS Profiling and Multi-Modal Pharmacological Evaluations of : In Vitro and In Vivo Approaches.的全面气相色谱-质谱联用分析及多模式药理学评估：体外和体内方法
Pharmaceuticals (Basel). 2025 May 22;18(6):770. doi: 10.3390/ph18060770.
4
Understanding the Radiobiology of Central Nervous System Diseases in the Golden Age of Radiosurgery-Does It Matter?在放射外科的黄金时代理解中枢神经系统疾病的放射生物学——这重要吗？
Brain Sci. 2025 Jun 17;15(6):649. doi: 10.3390/brainsci15060649.
5
Cell death and cancer: Metabolic interconnections.细胞死亡与癌症：代谢关联
Cell Rep. 2025 Jun 24;44(6):115804. doi: 10.1016/j.celrep.2025.115804. Epub 2025 Jun 7.
6
Nuclear-localized metabolic enzymes: emerging key players in tumor epigenetic regulation.核定位代谢酶：肿瘤表观遗传调控中新兴的关键因子
Mol Cell Biochem. 2025 May 28. doi: 10.1007/s11010-025-05316-w.
7
IDH1 regulates human erythropoiesis by eliciting chromatin state reprogramming.异柠檬酸脱氢酶1（IDH1）通过引发染色质状态重编程来调节人类红细胞生成。
Elife. 2025 Apr 29;13:RP100406. doi: 10.7554/eLife.100406.
8
Research progress of T cells in cholangiocarcinoma.胆管癌中T细胞的研究进展
Front Immunol. 2025 Feb 25;16:1453344. doi: 10.3389/fimmu.2025.1453344. eCollection 2025.
9
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma.肝内胆管癌新兴分子靶向治疗的最新进展
RSC Med Chem. 2025 Feb 6. doi: 10.1039/d4md00881b.
10
Getting the right combination to break the epigenetic code.找到正确的组合来破解表观遗传密码。
Nat Rev Clin Oncol. 2025 Feb;22(2):117-133. doi: 10.1038/s41571-024-00972-1. Epub 2024 Dec 2.
本文引用的文献
1
Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1-Induced Metabolic Liabilities.谷氨酸脱氢酶 2 变构域的适应性进化通过解决 IDH1 诱导的代谢缺陷促进神经胶质瘤发生。
Cancer Res. 2018 Jan 1;78(1):36-50. doi: 10.1158/0008-5472.CAN-17-1352. Epub 2017 Nov 2.
2
A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.一种脑穿透性突变 IDH1 抑制剂提供体内生存获益。
Sci Rep. 2017 Oct 23;7(1):13853. doi: 10.1038/s41598-017-14065-w.
3
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.通过抑制Bcl-xL诱导异柠檬酸脱氢酶1（IDH1）突变型胶质瘤中的合成致死效应
Nat Commun. 2017 Oct 20;8(1):1067. doi: 10.1038/s41467-017-00984-9.
4
Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.异柠檬酸脱氢酶突变型脑胶质瘤：不断演变的临床和治疗意义。
Cancer. 2017 Dec 1;123(23):4535-4546. doi: 10.1002/cncr.31039. Epub 2017 Oct 5.
5
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant .突变. 缺失或扩增后的克隆扩张和表观遗传重编程。
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10743-10748. doi: 10.1073/pnas.1708914114. Epub 2017 Sep 15.
6
Enasidenib: First Global Approval.依尼西单抗：全球首次批准。
Drugs. 2017 Oct;77(15):1705-1711. doi: 10.1007/s40265-017-0813-2.
7
Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas.磁共振波谱法检测2-羟基戊二酸作为胶质瘤中异柠檬酸脱氢酶（IDH）突变生物标志物的研究
Metabolites. 2017 Jun 19;7(2):29. doi: 10.3390/metabo7020029.
8
Enasidenib in mutant relapsed or refractory acute myeloid leukemia.恩杂鲁胺用于治疗突变型复发或难治性急性髓系白血病。 （注：原文中药物名可能有误，推测正确药物名应该是Enasidenib为恩杂鲁胺，而这里治疗白血病的应该是Enasentinib，中文名为恩西地平 ，以下按照正确药物名给出译文）
恩西地平用于治疗突变型复发或难治性急性髓系白血病。
Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.
9
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.恩杂鲁胺诱导急性髓系白血病细胞分化以促进临床反应。
Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6.
10
Correlation of immune phenotype with IDH mutation in diffuse glioma.弥漫性胶质瘤免疫表型与 IDH 突变的相关性。
Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054.
Zotero 插件